EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal refux disease: A double blind, placebo controlled, randomised trial



Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal refux disease: A double blind, placebo controlled, randomised trial



Gut 53(2): 174-179, February



Background: The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease (GORD) is controversial. We hypothesised that H pylori eradication leads to worsened control of reflux disease. Methods: Consecutive patients with weekly reflux symptoms were prospectively recruited for endoscopy and symptom evaluation. Patients were enrolled if they had H pylori infection and required long term acid suppressants. Eligible patients were randomly assigned to omeprazole triple therapy (HpE group) or omeprazole with placebo antibiotics (Hp+ group) for one week. Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief. This was followed by a maintenance dose of 10 mg daily for up to 12 months. The primary study end point was the probability of treatment failure within 12 months, which was defined as either incomplete resolution of symptoms or oesophagitis at the initial treatment phase, or relapse of symptoms and oesophagitis during the maintenance phase. Predictors of treatment failure were determined by Cox's proportional hazards model. Results: A total of 236 GORD patients were screened and 113 (47.9%) were positive for H pylori; 104 (92%) patients were included in the intention to treat analysis (53 in the HpE group and 51 in the Hp+ group). Thirty one patients (30%) had erosive oesophagitis at baseline. H pylori was eradicated in 98% of the HpE group and in 3.9% of the Hp+ group. Overall, 15 patients (28.3%) in the HpE group and eight patients (15.7%) in the Hp+ group had treatment failure. The 12 month probability of treatment failure was 43.2% (95% confidence interval (CI) 29.9-56.5%) in the HpE group and 21.1% (95% CI 9.9-32.3%) in the Hp+ group (log rank test, p=0.043). In the Cox proportional hazards model, after adjustment for the covariates age, sex, erosive oesophagitis, hiatus hernia, degree of gastritis, and severity of symptoms at baseline, H pylori eradication was the only predictor of treatment failure (adjusted hazard ratio 2.47 (95% CI 1.05-5.85)). Conclusion: H pylori eradication leads to more resilient GORD.

(PDF emailed within 1 workday: $29.90)

Accession: 011989895

Download citation: RISBibTeXText

PMID: 14724146



Related references

The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study. United European Gastroenterology Journal 1(4): 226-235, 2014

Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease? - A randomised double blind study. Gut 44(SUPPL 1): A112, April, 1999

Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. BMJ 318(7187): 833-837, March 27, 1999

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. Bmj 318(7187): 833-837, 1999

Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. Bmj 328(7453): 1417-1417, 2004

Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. Journal of Pediatric Gastroenterology and Nutrition 48(4): 431-436, 2009

Randomized, double-blind, placebo-controlled trial: Effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. Revista de Gastroenterologia de Mexico 74(2): 142-143, 2014

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Bmj 318(7187): 833-837, 1999

The effect of eradication of Helicobacter pylori on symptoms of non-ulcer dyspepsia A randomized double-blind placebo controlled trial. Gut 37(SUPPL 1): A56, 1995

Effect of H pylori eradication on maintenance treatment of gastroesophageal reflux disease A double-blind placebo-controlled randomized trial. Gastroenterology 122(4 Suppl 1): A-101, April, 2002

Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. Journal of Gastroenterology 42(8): 690-693, 2007

Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. Nutrition, Metabolism, and Cardiovascular Diseases 26(10): 893-898, 2016

Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics 39(6): 595-602, 2014

Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 12(5): 477-485, 2007

Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 357(9270): 1738-1742, 2001